Bishoy M. Faltas, MD, Fellow, Hematology/Oncology, Weill Cornell Medical College, discusses genomic testing in urothelial cancer.
Bishoy M. Faltas, MD, Fellow, Hematology/Oncology, Weill Cornell Medical College, discusses genomic testing in urothelial cancer (UC).
In UC alterations in FGFR3, PIK3CA, and CDKN2A have become actionable targets for therapy. Clinical research has begun to explore how genomic alterations interact with tumors to shape understanding that can aid in treatment.
Transcription:
0:08 | We've been learning a lot over the past few years about the genomic underpinnings of bladder cancer. And the role of genomic testing is expanding almost every year as we learn more about the role of genomic alterations in the pathogenesis and the natural history, and response to treatment in patients with bladder cancer.
0:37 | So, for example, this year, we are learning a lot more about the germline the role of the germline variants in urothelial. cancer and germline variants are these alterations that we're all born with, that are inherited. And we're this year we published a manuscript in Nature Communications that looked at the role of germline alterations or germline variants in bladder cancer patients, and we identified several common germline variants in these patients, which is consistent with other findings that are emerging from other groups. And we're now trying to understand how these germline alterations interact with the cancer somatic alterations to shape the course of bladder cancer.
FDA Approves Nogapendekin Alfa Inbakicept for BCG-Unresponsive NMIBC Carcinoma In Situ
April 22nd 2024Patients with Bacillus Calmette-Guérin-unresponsive non-muscle-invasive bladder cancer carcinoma in situ now have a new treatment option following the FDA’s approval of nogapendekin alfa.
Read More
FDA Accepts IND for UGN-103 in Low-Grade Intermediate-Risk NMIBC
April 15th 2024An investigational new drug application for UGN-103 was accepted by the FDA. A phase 3 study to assess the safety and efficacy of the agent in low-grade intermediate-risk non-muscle invasive bladder cancer is anticipated.
Read More
Study Shows Desire for Bladder-Sparing Treatments in High-Risk NMIBC
April 2nd 2024In an interview with Targeted Oncology, Joseph M. Jacob, MD, discussed how bladder preservation is the top reason for refusal of radical cystectomy in the TAR-200 monotherapy cohort of the SunRISe-1 study.
Read More